Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, has announced that it has been selected to be part of the highly limited Specialty Pharmacy network of Zydelig (idelalisib) tablets. PharMerica Corporation (PMC) is a significant investor in Onco360.
Subscribe to our email newsletter
Zydelig has been approved by The U.S. Food and Drug Administration (FDA) for the treatment of three different B-cell blood cancers:
1. In combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy.
2. As monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies.
3. As monotherapy for patients with small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
Oncology is the largest and fasted-growing segment of specialty drug expenditures:
- The global oncology market is estimated to exceed $47 billion.
- Annual oncology drug spending is expected to increase to $175 billion by 2020.
- More than 250,000 Americans are estimated to be affected by the CLL, FL and SLL cancers.
"This selection is an important milestone in Onco360’s strategy to offer an innovative, diversified portfolio of pharmacy and clinical solutions," said Vice Chairman of Onco360, Burt Zweigenhaft.
"We have confidence in the potential of Zydelig to achieve a strong market share position and further bolster our leadership in the specialty oncology pharmacy market. This relationship also continues to enhance our mission of providing the highest level of support to those battling cancer and helping treat the unmet needs of thousands of people afflicted with life-threatening illness."
"We are pleased to be among the select few companies working with Gilead Sciences to dispense Zydelig. This selection reflects Onco360’s strong reputation in the marketplace and our Oncology Pharmacy team’s commitment to fulfilling our patient-centric mission and values," said Senior Vice President of Trade Channel Strategy Relations for Onco360, Ron Bookman, J.D.
Zydelig is immediately available for order through Onco360 and its network of OncoMed Pharmacies. Prescription orders can be placed by:
- Downloading the Zydelig Order Form from Onco360.com/Order and faxing it to 877-662-6355;
- Calling 877-662-6633; or
- e-Prescribing to OncoMed, Great Neck, NY 11021 under the retail tab in your EMR/EHR.